Please ensure Javascript is enabled for purposes of website accessibility

Why Emergent BioSolutions Stock Fell Today

By Keith Speights - Updated Apr 13, 2021 at 3:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pause on use of Johnson & Johnson's COVID-19 vaccine had a ripple impact.

What happened

Shares of Emergent BioSolutions (EBS 0.21%) were trading 3.8% lower as of 3:01 p.m. EDT on Tuesday. The decline came after the U.S. Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA) called for a pause in the administration of Johnson & Johnson's (JNJ -0.47%) COVID-19 vaccine. 

So what

Emergent BioSolutions contracted to manufacture J&J's COVID-19 vaccine. Therefore, any long-term issues with the vaccine could potentially hurt Emergent.

Two rows of vaccine vials. A syringe is inserted into a vial at the front.

Image source: Getty Images.

The CDC and FDA stated that they're reviewing six cases of a rare type of blood clot occurring in individuals after receiving the vaccine. The agencies said that the pause is being recommended "out of an abundance of caution" while the review moves forward.

However, this review is expected to take only a few days. The pause on administration could be lifted once the review is over, although the CDC and FDA will probably issue new guidelines for healthcare providers.

Now what

There's a bigger issue for Emergent BioSolutions that could weigh on the performance of the healthcare stock even if the questions related to blood clotting with J&J's vaccine are resolved. The company made a huge mixup with the production of a large batch of the vaccine several weeks ago. This resulted in the U.S. government giving Johnson & Johnson control of the manufacturing facility. This highly visible mistake could negatively impact Emergent BioSolutions' ability to win contract manufacturing deals in the future. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Emergent BioSolutions. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Emergent BioSolutions Inc. Stock Quote
Emergent BioSolutions Inc.
$28.49 (0.21%) $0.06
Johnson & Johnson Stock Quote
Johnson & Johnson
$166.80 (-0.47%) $0.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.